Infratil (IFT.NZ) FY25 Result: CDC deferral and higher One NZ cost drive FY26 downgrade, but FY27 growth intact; Neutral

Investment Rating - The report assigns a Neutral rating to Infratil (IFT.NZ) [1][4][15] Core Insights - The FY25 results were softer than expected, with Proportionate EBITDAF declining by 4% compared to Goldman Sachs estimates, leading to a downgrade in FY26 guidance to NZ$1,000-1,050 million, which is 3%-5% lower than previous estimates [1][4] - Infratil plans to monetize NZ$1 billion of assets that are unlikely to scale under the current ownership model, with the capital reinvested in businesses that can provide more meaningful returns [2] - The healthcare portfolio is performing strongly, with RHCNZ and Qscan expecting accelerating EBITDAF growth into FY26 [2] - Longroad Energy is targeting an OpCo run-rate EBITDA of US$370 million by March 2026, driven by contributions from projects that are operational or under construction [2] Financial Performance - FY26-28 EBITDAF estimates have been revised down by 3% to 4% due to CDC deferrals and increased costs for One NZ [4][13] - The 12-month target price is set at NZ$10.70, reflecting a 3% decrease from previous estimates [4][14] - Key financial metrics include projected revenue growth of 22.7% for FY25, with a decline in EPS for FY26 expected at NZ$0.13, compared to a previous estimate of NZ$0.09 [10][11] Investment Thesis - Infratil is positioned to benefit from increased digital consumption and AI adoption, particularly through its investments in digital infrastructure and renewable energy [15] - Despite positive long-term themes, the current market valuation appears to have already factored in these growth prospects, leading to a Neutral rating [15]